Home > Cardiology > AHA 2020 > Coronary and Valve Disease > Ticagrelor not superior to clopidogrel after elective PCI

Ticagrelor not superior to clopidogrel after elective PCI

Presented By
Prof. Johanne Silvain, Sorbonne University, France
Conference
AHA 2020
Trial
Phase 3, ALPHEUS

In the ALPHEUS trial, ticagrelor was not superior to clopidogrel at reducing the incidence of periprocedural myocardial infarction (MI) for patients undergoing elective percutaneous coronary intervention (PCI). The authors concluded that aspirin/clopidogrel remains the standard of care for elective PCI and more potent P2Y12 inhibitors (i.e. ticagrelor and prasugrel) for acute coronary syndromes [1,2].

For patients undergoing elective PCI, aspirin/clopidogrel is the recommended dual antiplatelet therapy (DAPT) regimen. PCI-related MI and myocardial injury are frequent complications that impact long-term clinical prognosis. Stronger platelet inhibition could potentially lower these events and make the procedure safer, explained Prof. Johanne Silvain (Sorbonne University, France). The ALPHEUS study (NCT02617290) aimed to examine whether ticagrelor was super...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on